Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
Predictive Oncology (NASDAQ: POAI) announced that CEO Raymond Vennare will present at the BIO International Convention 2024 in San Diego from June 3-6. Vennare will discuss the company's AI-driven drug discovery capabilities, which leverage a proprietary biobank of over 150,000 tumor samples. The firm's assets include advanced AI, a CLIA-certified wet lab, and pathology slides, enabling robust predictions through real-world experimentation. The presentation, titled 'Novel AI Driven Insights to Guide Early Drug Discovery,' is scheduled for June 3rd at 3:45 PM PDT. This event is a significant platform for biopharmaceutical stakeholders globally.
- CEO Raymond Vennare's presentation at a prestigious event like BIO International Convention showcases the company's industry relevance.
- Utilization of a proprietary biobank with over 150,000 tumor samples is a strong asset for early drug discovery.
- Possession of advanced AI and machine learning capabilities positions Predictive Oncology as a leader in AI-driven drug discovery.
- A CLIA-certified wet lab enhances the company's ability to conduct real-world experimentation, adding credibility to its predictions.
- The company's efforts in introducing tumor heterogeneity early in drug discovery may result in more effective oncologic treatments.
- The press release lacks concrete data on financial performance, which may concern investors looking for financial health indicators.
- Dependence on proprietary technology and biobank might pose risks if competitors develop similar or superior capabilities.
- The announcement does not address potential challenges or risks in deploying AI-driven drug discovery.
- There is no mention of partnerships or collaborations, which could be pivotal for commercial success and market penetration.
- The event's impact on the stock price remains uncertain without tangible results or business developments presented.
Presentation to highlight Company’s novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond Vennare, Chief Executive Officer, is scheduled to deliver a company overview presentation at the BIO International Convention 2024, which is being held June 3-6 in San Diego.
“We are very pleased to participate in this year’s Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. “With our unique portfolio of assets, which includes advanced AI and active machine learning capabilities, a CLIA-certified wet lab, and a vast biobank of hundreds of thousands of tumor samples and pathology slides, we are able to confidently support our predictions through real-world experimentation by introducing tumor heterogeneity into the earliest phases of drug discovery. I look forward to highlighting these capabilities, which I believe set us apart from our peers and will allow us to be a leader in this rapidly growing field of AI-driven drug discovery.”
Presentation details:
| Title: | Novel AI Driven Insights to Guide Early Drug Discovery |
| Date/time: | Monday, June 3rd, 3:45pm PDT (6:45pm EDT) |
| For more information: https://convention.bio.org/about-bio | |
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with
Investor Relations Contact
Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
FAQ
What is the significance of Predictive Oncology's presentation at the BIO International Convention 2024?
When and where will Predictive Oncology's presentation take place?
What will be discussed in Predictive Oncology's presentation?
How many tumor samples does Predictive Oncology's biobank contain?
What are the key assets of Predictive Oncology mentioned in the press release?
